Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity

Am J Hematol. 2020 Mar;95(3):E60-E62. doi: 10.1002/ajh.25702. Epub 2019 Dec 30.

Authors

Marcella Tschautscher¹, Dragan Jevremovic², Francis K Buadi¹, Martha Q Lacy¹, Morie A Gertz¹, Angela Dispenzieri¹, Prashant Kapoor¹, David Dingli¹, Lisa Hwa¹, Amie Fonder¹, Miriam Hobbs¹, Suzanne Hayman¹, John Lust¹, Stephen Russell³, Nelson Leung⁴, Ronald Go¹, Yi Lin¹, Wilson Gonsalves¹, Taxiarchis Kourelis¹, Rahma Warsame¹, Robert A Kyle¹, Vincent Rajkumar¹, Shaji Kumar¹

Affiliations

¹ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
² Division of Hematopathology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
³ Division of Molecular Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
⁴ Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.

PMID: 31840857
DOI: 10.1002/ajh.25702

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Disease-Free Survival
Female
Humans
Male
Multiple Myeloma* / blood
Multiple Myeloma* / immunology
Multiple Myeloma* / mortality
Multiple Myeloma* / therapy
Neoplasm, Residual
Retrospective Studies
Survival Rate

Grants and funding

Mayo Clinic/International